Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27734144 | 0.88 | — | — | |
| SCHEMBL28143169 | 0.87 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL4854880 | 0.84 | HTR6 (0.30) | — | |
| SCHEMBL4080655 | 0.82 | — | — | |
| SCHEMBL446064 | 0.82 | — | — | |
| SCHEMBL27778680 | 0.75 | HTR6 (0.33) | — | |
| SCHEMBL3381802 | 0.74 | — | — | |
| SCHEMBL6601682 | 0.71 | — | — | |
| SCHEMBL24581554 | 0.67 | MEN1 (0.42) | CYP2A13ALDH1A1HPGDL3MBTL1SMN1; SMN2 | |
| SCHEMBL23097056 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110520422-B | Novel pyridonecarboxylic acid derivative or salt thereof | 涌永制药株式会社 | 2023-09-05 | — | — | CN | disclosed |
| EP-3523291-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | Mission Therapeutics Limited (GB) | 2019-08-14 | — | — | EP | disclosed |
| WO-2018065768-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
| EP-2464693-B1 | AFTER CLEARING AGENT | HUNTSMAN ADV MAT SWITZERLAND (CH) | 2015-01-28 | — | — | EP | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| CN-103328480-A | Condensed imidazolylimidazoles as antiviral compounds | GILEAD SCIENCES INC | 2013-09-25 | — | — | CN | disclosed |
| CN-101784548-B | Purine derivatives and their use as modulators of Toll-like receptor 7 | GILEAD SCIENCES INC | 2013-07-17 | — | — | CN | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| CN-101490023-B | Modulators of the Pharmacokinetic Properties of Therapeutic Agents | GILEAD SCIENCES INC | 2013-05-29 | — | — | CN | disclosed |
| CN-103052631-A | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES INC | 2013-04-17 | — | — | CN | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| CN-1501937-A | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | �Ʒ� | 2004-06-02 | — | — | CN | disclosed |
| CN-1478093-A | Coupling process and intermediates useful for preparing cephalosphorins | �Ʒ� | 2004-02-25 | — | — | CN | disclosed |
| CN-1478094-A | Process and ester derivatives for the preparation of cephalosporins | �Ʒ� | 2004-02-25 | — | — | CN | disclosed |
| CN-1355809-A | Immunomodulatory steroids, in particular hemihydrate of 16 alpha-bromoepiandrosterone | HOLLIS EDEN PHARMACEUTICALS (US) | 2002-06-26 | — | — | CN | disclosed |
| CN-1064351-C | Substituted 2, 3-dihydroindenyleneacetylguanidines, method for the production thereof, use thereof as medicaments or use thereof as diagnostic agents and medicaments containing the same | HOECHST AG (DE) | 2001-04-11 | — | — | CN | disclosed |
| CN-1064043-C | Process for the preparation of 1, 5-benzothiazepine * derivatives | TANABE SEIYAKU CO (JP) | 2001-04-04 | — | — | CN | disclosed |
| CN-1244200-A | Nucleotide analogs | GILEAD SCIENCES INC (US) | 2000-02-09 | — | — | CN | disclosed |
| CN-1172104-A | Substituted 2, 3-dihydroindenyleneacetylguanidines, method for the production thereof, use thereof as medicaments or use thereof as diagnostic agents and medicaments containing the same | HOECHST AG (DE) | 1998-02-04 | — | — | CN | disclosed |
| CN-1160713-A | Process for the preparation of 1, 5-benzothiazepine * derivatives | TANABE SEIYAKU CO (JP) | 1997-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | CYP2A13 4289/4885ALDH1A1 3925/4885HPGD 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.